News & Media

Si l'intestin a un charme discret, son potentiel clinique ne l'est pas. Pour développer des médicaments ciblant le microbiote afin de traiter l'obésité et les maladies cardio- métaboliques associées, la biotech bordelaise LNC Therapeutics a trouvé, fin septembre, 6,5 millions d'euros.

+ Find out more

Obésité : LNC Therapeutics, qui met au point un traitement contre l'obésité et les maladies cardiométaboliques, a bouclé un troisième tour de table de 6,5 millions d'euros auprès de ses investisseurs historiques, dont Seventure Partners.

+ Find out more

LNC Therapeutics has raised €6.5m in a Series C funding round as the company announces a new chief science officer and steps up an ‘ambitious’ microbiota-orientated strategy that it hopes will drive an IPO by the end of 2019.

+ Find out more

LNC Therapeutics is ready to take its oral microbiome-based therapeutic to market for obesity. Investors have contributed a bit of cash to get it there. Bordeaux-based LNC Therapeutics has raked in €6.5M in a Series C. It has raised a total of €16.5M since it was founded in 2010. Seventure Partners, a leading VC focused on the microbiome, led...

+ Find out more

LNC Therapeutics, a French company specializing in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, raised €6.5 million ($7.7 million) in Series C funding.

+ Find out more